Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham Mailankody|JAMA Internal Medicine|2017Cited by 497
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Sham Mailankody, Kevin De Jesús|Nature Reviews Clinical Oncology|2017Cited by 430
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Sean M. Devlin et al.|New England Journal of Medicine|2022Cited by 383
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Ola Landgren, Yvonne Wall et al.|JAMA Oncology|2015Cited by 309
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and CreativityTito Fojo, Andrew W. Lo, Sham Mailankody|JAMA Otolaryngology–Head & Neck Surgery|2014Cited by 301